Monitor the final written decision expected within a year. The patent's subject matter (analytics, algorithm architecture, data processing) is broad — any impact on AMD would depend on whether the patent is tied to specific AMD products, which the decision does not state.
Price Chart
Executive Summary
The PTAB granted institution of inter partes review in IPR2026-00358, allowing AMD to proceed with its challenge to Fermat International's patent covering analytics and data processing system architecture. This is an interlocutory ruling — no claims have been cancelled yet, and a final written decision is expected within about a year.
PTAB Trial Details
Key Facts
- PTAB instituted IPR trial on U.S. Patent 11,886,750 owned by Fermat International, Inc.
- AMD is the petitioner challenging the patent's validity.
- Institution granted means the Board found a reasonable likelihood AMD would prevail on at least one challenged claim.
- No claims have been cancelled — this is an interlocutory decision.
- A final written decision is due within approximately 12 months.
Financial Impact
No financial figures stated in the decision. The patent covers analytics and data processing system architecture; no specific AMD products or revenue lines are tied to it in the decision.
Risk Factors
- If the final decision cancels claims, Fermat may appeal to the Federal Circuit, extending uncertainty.
- If the patent survives, AMD could face infringement exposure, but the decision does not quantify any potential damages or licensing costs.
Investment Themes
Documents Analyzed
This report is based on 1 PTAB decision.
| Document | Accession Number |
|---|---|
| PTAB-TRIAL Data (Synthetic) | ptab-IPR2026-00358-ins-AMD |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | Institutional Cluster | $516.79 | awaiting T+60 | — | $531.28 (+2.80%) |
Oct 21, 2026 6d ago | PTAB Trial | $507.93 | awaiting T+60 | — | $531.28 (+4.60%) |
Oct 20, 2026 7d ago | PTAB Trial | $552.72 | awaiting T+60 | — | $531.28 (−3.88%) |
Oct 19, 2026 8d ago | PTAB Trial | $534.74 | awaiting T+60 | — | $531.28 (−0.65%) |
Oct 19, 2026 8d ago | PTAB Trial | $534.74 | awaiting T+60 | — | $531.28 (−0.65%) |
Sep 28, 2026 28d ago | Press Release | $607.57 | awaiting T+60 | — | $531.28 (−12.56%) |
Sep 17, 2026 5w ago | Insider Cluster | $559.82 | awaiting T+60 | — | $531.28 (−5.10%) |
Aug 27, 2026 8w ago | Insider Cluster | $465.58 | awaiting T+60 | — | $531.28 (−14.11%) |
Aug 26, 2026 8w ago | Insider Cluster | $476.67 | awaiting T+60 | — | $531.28 (+11.46%) |
Aug 21, 2026 9w ago | ANALYST-UPGRADE | $473.25 | awaiting T+60 | — | $531.28 (+12.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time PTAB Decision Intelligence
Market-moving PTAB patent decisions analyzed within minutes. Trial institutions, denials, final written decisions, and more — parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers